Journal
FEBS LETTERS
Volume 594, Issue 4, Pages 646-664Publisher
WILEY
DOI: 10.1002/1873-3468.13648
Keywords
allostery; cancer; enzymology; mutation
Funding
- MIT Undergraduate Research Opportunities Program
- HHMI graduate student fellowship
- Sara and Frank McKnight Fund for Biochemical Research
- NIH [DP5OD021365, R01CA168653, P30CA1405141]
- Burroughs Wellcome Fund
- Ludwig Center at MIT
- SU2C
- Lustgarten Foundation
- MIT Center for Precision Cancer Medicine
- HHMI
- [T32GM007287]
Ask authors/readers for more resources
Mammalian pyruvate kinase catalyzes the final step of glycolysis, and its M2 isoform (PKM2) is widely expressed in proliferative tissues. Mutations in PKM2 are found in some human cancers; however, the effects of these mutations on enzyme activity and regulation are unknown. Here, we characterized five cancer-associated PKM2 mutations, occurring at various locations on the enzyme, with respect to substrate kinetics and activation by the allosteric activator fructose-1,6-bisphosphate (FBP). The mutants exhibit reduced maximal velocity, reduced substrate affinity, and/or altered activation by FBP. The kinetic parameters of five additional PKM2 mutants that have been used to study enzyme function or regulation also demonstrate the deleterious effects of mutations on PKM2 function. Our findings indicate that PKM2 is sensitive to many amino acid changes and support the hypothesis that decreased PKM2 activity is selected for in rapidly proliferating cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available